Action Point Financial Planning’s Kymera Therapeutics KYMR Stock Holding History

Action Point Financial Planning’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.49K	Buy	+14	New	+$1.2K	﹤0.01%	2354

Other funds holding KYMR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Action Point Financial Planning's KYMR Position: Q2 2026 in Review

Action Point Financial Planning opened a new position in Kymera Therapeutics (KYMR) in Q2 2026: 14 shares worth $1.49K. The stake represents ﹤0.01% of the portfolio and ranks #2354 among its holdings.

273 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

Action Point Financial Planning held 14 shares of Kymera Therapeutics worth $1.49K as of Q2 2026.
Kymera Therapeutics was a new Action Point Financial Planning position in Q2 2026.
Kymera Therapeutics made up ﹤0.01% of Action Point Financial Planning's portfolio in Q2 2026, its #2354 holding.
273 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Action Point Financial Planning's 13F filing for Q2 2026, filed 14 Aug 2026.